News

Combination therapy of an anti-platelet-derived growth factor aptamer plus an anti-vascular endothelial lesion regression in 91% of eyes with choroidal neovascularization compared with only 16% of eyes with anti-VEGF monotherapy.

There has been a new development in the way Current Procedural Terminology (CPT) Category III codes, also known as T-codes, are viewed, reimbursed, and treated in the means of medical billing and coding.

Ophthalmic surgical instrument manufacturers and distributors work in a constantly evolving and increasingly global marketplace, and in late 2009, are meeting challenges posed by new procedures and changing government regulations.

The U.S. District Court for the District of Delaware has ruled in favor of Allergan Inc. in its patent infringement lawsuit against two sets of defendants seeking to market purported generic versions of the company?s formulations of brimonidine tartrate 0.1% and 0.15% (Alphagan P) for ocular hypertension and glaucoma. Specifically, the court ruled that Allergan's five patents related to the ophthalmic solutions are valid and enforceable.

Results of a second phase study showed patients with category 3 dry age-related macular degeneration (AMD) can achieve increased and sustained visual acuity levels with administration of correct carotenoids, vitamins and minerals.

Consequences of reform

J.C. Noreika, MD, MBA, submitted a letter to Sen. Sherrod Brown (D-OH), outlining nine possible unintended consequences to health-care reform.

Results from a series of bench studies evaluating a new 25+-gauge vitrectomy proble and trocar system highlight the benefits and improved performance of this technology compared with previous instrumentation for microincision vitrectomy surgery.

Data analyses collected in a phase III clinical trial show a strong benefit of intravitreal ranibizumab for clearing macular edema and rehabilitating vision in patients who have suffered a branch retinal vein occlusion.